Novavax NVX-COV2373 Triggers Neutralization of Omicron Sub-lineages

Overview

Journal Sci Rep

Specialty Science

Date 2023 Jan 21

PMID 36681693

Authors

Jinal N Bhiman

Simone I Richardson

Bronwen E Lambson

Prudence Kgagudi

Nonkululeko Mzindle

Haajira Kaldine

Carol Crowther

Glenda Gray

Linda-Gail Bekker

Vivek Shinde

Chijioke Bennett

Gregory M Glenn

Shabir A Madhi

Penny L Moore

Affiliations

Soon will be listed here.

Abstract

The SARS-CoV-2 Omicron (B.1.1.529) Variant of Concern (VOC) and its sub-lineages (including BA.2, BA.4, BA.5, BA.2.12.1) contain spike mutations that confer high level resistance to neutralizing antibodies induced by vaccination with ancestral spike or infection with previously circulating variants. The NVX-CoV2373 vaccine, a protein nanoparticle vaccine containing the ancestral spike sequence, has value in countries with constrained cold-chain requirements. Here we report neutralizing titers following two or three doses of NVX-CoV2373. We show that after two doses, Omicron sub-lineages BA.1 and BA.4/BA.5 were resistant to neutralization by 72% (21/29) and 59% (17/29) of samples respectively. However, after a third dose of NVX-CoV2373, we observed high titers against Omicron BA.1 (GMT: 1,197) and BA.4/BA.5 (GMT: 582), with responses similar in magnitude to those triggered by three doses of an mRNA vaccine. These data are of particular relevance as BA.4/BA.5 is dominating in multiple locations, and highlight the potential utility of the NVX-CoV2373 vaccine as a booster in resource-limited environments.

Citing Articles

Immunogenicity and safety following a homologous booster dose of a SARS-CoV-2 recombinant spike protein vaccine with Matrix-M adjuvant (NVX-CoV2373) versus a primary series in people living with and without HIV-1 infection in South Africa: A....

Shinde V, Lombard Koen A, Hoosain Z, Archary M, Bhorat Q, Fairlie L Hum Vaccin Immunother. 2024; 20(1):2425147.

PMID: 39666396 PMC: 11789733. DOI: 10.1080/21645515.2024.2425147.

Hybrid Immunity against SARS-CoV-2 Variants: A Narrative Review of the Literature.

Tsagkli P, Geropeppa M, Papadatou I, Spoulou V Vaccines (Basel). 2024; 12(9).

PMID: 39340081 PMC: 11436074. DOI: 10.3390/vaccines12091051.

Vaccination and Therapeutics.

Abdella W, Selim A, Diab S, Qobeia E, Elgazzar A Adv Exp Med Biol. 2024; 1457:165-184.

PMID: 39283426 DOI: 10.1007/978-3-031-61939-7_9.

Immunogenicity and efficacy of XBB.1.5 rS vaccine against the EG.5.1 variant of SARS-CoV-2 in Syrian hamsters.

Soudani N, Bricker T, Darling T, Seehra K, Patel N, Guebre-Xabier M J Virol. 2024; 98(10):e0052824.

PMID: 39230305 PMC: 11494984. DOI: 10.1128/jvi.00528-24.

Validation of a Pseudovirus Neutralization Assay for Severe Acute Respiratory Syndrome Coronavirus 2: A High-Throughput Method for the Evaluation of Vaccine Immunogenicity.

Cai Z, Kalkeri R, Wang M, Haner B, Dent D, Osman B Microorganisms. 2024; 12(6).

PMID: 38930583 PMC: 11205394. DOI: 10.3390/microorganisms12061201.

References

Munro A, Janani L, Cornelius V, Aley P, Babbage G, Baxter D . Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial. Lancet. 2021; 398(10318):2258-2276. PMC: 8639161. DOI: 10.1016/S0140-6736(21)02717-3. View

Mallory R, Formica N, Pfeiffer S, Wilkinson B, Marcheschi A, Albert G . Safety and immunogenicity following a homologous booster dose of a SARS-CoV-2 recombinant spike protein vaccine (NVX-CoV2373): a secondary analysis of a randomised, placebo-controlled, phase 2 trial. Lancet Infect Dis. 2022; 22(11):1565-1576. PMC: 9365313. DOI: 10.1016/S1473-3099(22)00420-0. View

Bowen J, Addetia A, Dang H, Stewart C, Brown J, Sharkey W . Omicron spike function and neutralizing activity elicited by a comprehensive panel of vaccines. Science. 2022; 377(6608):890-894. PMC: 9348749. DOI: 10.1126/science.abq0203. View

Viana R, Moyo S, Amoako D, Tegally H, Scheepers C, Althaus C . Rapid epidemic expansion of the SARS-CoV-2 Omicron variant in southern Africa. Nature. 2022; 603(7902):679-686. PMC: 8942855. DOI: 10.1038/s41586-022-04411-y. View

Cele S, Jackson L, Khoury D, Khan K, Moyo-Gwete T, Tegally H . Omicron extensively but incompletely escapes Pfizer BNT162b2 neutralization. Nature. 2022; 602(7898):654-656. PMC: 8866126. DOI: 10.1038/s41586-021-04387-1. View

Cao Y, Yisimayi A, Jian F, Song W, Xiao T, Wang L . BA.2.12.1, BA.4 and BA.5 escape antibodies elicited by Omicron infection. Nature. 2022; 608(7923):593-602. PMC: 9385493. DOI: 10.1038/s41586-022-04980-y. View

Tegally H, Moir M, Everatt J, Giovanetti M, Scheepers C, Wilkinson E . Emergence of SARS-CoV-2 Omicron lineages BA.4 and BA.5 in South Africa. Nat Med. 2022; 28(9):1785-1790. PMC: 9499863. DOI: 10.1038/s41591-022-01911-2. View

Heath P, Galiza E, Baxter D, Boffito M, Browne D, Burns F . Safety and Efficacy of NVX-CoV2373 Covid-19 Vaccine. N Engl J Med. 2021; 385(13):1172-1183. PMC: 8262625. DOI: 10.1056/NEJMoa2107659. View

. WHO lists 9th COVID-19 vaccine for emergency use with aim to increase access to vaccination in lower-income countries. Saudi Med J. 2022; 43(1):119-120. PMC: 9280553. View

10.

Zhang Z, Mateus J, Coelho C, Dan J, Rydyznski Moderbacher C, Galvez R . Humoral and cellular immune memory to four COVID-19 vaccines. Cell. 2022; 185(14):2434-2451.e17. PMC: 9135677. DOI: 10.1016/j.cell.2022.05.022. View

11.

Garcia-Beltran W, Denis K, Hoelzemer A, Lam E, Nitido A, Sheehan M . mRNA-based COVID-19 vaccine boosters induce neutralizing immunity against SARS-CoV-2 Omicron variant. Cell. 2022; 185(3):457-466.e4. PMC: 8733787. DOI: 10.1016/j.cell.2021.12.033. View

12.

Shinde V, Bhikha S, Hoosain Z, Archary M, Bhorat Q, Fairlie L . Efficacy of NVX-CoV2373 Covid-19 Vaccine against the B.1.351 Variant. N Engl J Med. 2021; 384(20):1899-1909. PMC: 8091623. DOI: 10.1056/NEJMoa2103055. View

13.

Richardson S, Madzorera V, Spencer H, Manamela N, van der Mescht M, Lambson B . SARS-CoV-2 Omicron triggers cross-reactive neutralization and Fc effector functions in previously vaccinated, but not unvaccinated, individuals. Cell Host Microbe. 2022; 30(6):880-886.e4. PMC: 8947963. DOI: 10.1016/j.chom.2022.03.029. View

14.

Dunkle L, Kotloff K, Gay C, Anez G, Adelglass J, Barrat Hernandez A . Efficacy and Safety of NVX-CoV2373 in Adults in the United States and Mexico. N Engl J Med. 2021; 386(6):531-543. PMC: 8693692. DOI: 10.1056/NEJMoa2116185. View

15.

Rambaut A, Holmes E, OToole A, Hill V, McCrone J, Ruis C . A dynamic nomenclature proposal for SARS-CoV-2 lineages to assist genomic epidemiology. Nat Microbiol. 2020; 5(11):1403-1407. PMC: 7610519. DOI: 10.1038/s41564-020-0770-5. View